Davis Investment Partners, LLC Incyte Corp Transaction History

Davis Investment Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	BUY	$51.18 - $63.75 $298,072 - $371,280	5,824 Added 48.89%	17,737 $1.13 Billion
Q1 2024 Apr 15, 2024	SELL	$56.55 - $66.59 $51,064 - $60,130	-903 Reduced 7.05%	11,913 $655 Million
Q4 2023 Jan 12, 2024	BUY	$52.16 - $64.19 $20,133 - $24,777	386 Added 3.11%	12,816 $853 Million
Q3 2023 Oct 10, 2023	BUY	$57.77 - $65.93 $751 - $857	13 Added 0.1%	12,430 $731 Million
Q2 2023 Aug 01, 2023	SELL	$60.95 - $75.51 $72,042 - $89,252	-1,182 Reduced 8.69%	12,417 $795 Million
Q1 2023 Apr 14, 2023	SELL	$70.23 - $86.01 $27,389 - $33,543	-390 Reduced 2.79%	13,599 $988 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $939,781 - $1.18 Million	13,989 New	13,989 $1.12 Billion

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Davis Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Davis Investment Partners, LLC with notifications on news.